Efrat Dotan

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. pmc A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    J Gastrointest Cancer 43:562-9. 2012
  2. pmc Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
    E Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Br J Cancer 106:748-55. 2012
  3. pmc Challenges in the management of older patients with colon cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    J Natl Compr Canc Netw 10:213-24; quiz 225. 2012
  4. pmc Challenges in the management of stage II colon cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Semin Oncol 38:511-20. 2011
  5. doi request reprint Optimizing chemotherapy regimens for patients with early-stage breast cancer
    Efrat Dotan
    Fox Chase Cancer Center, Philadelphia, PA 19111 2412, USA
    Clin Breast Cancer 10:E8-15. 2010
  6. pmc Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity
    Elizabeth R Plimack
    Elizabeth R Plimack, Rosalia Viterbo, Eric A Ross, Richard E Greenberg, David Y T Chen, Yu Ning Wong, Alexander Kutikov, Efrat Dotan, Essel Dulaimi, Reza Mehrazin, Robert G Uzzo, and Gary R Hudes, Fox Chase Cancer Center, Temple Health Jean H Hoffman Censits, Edouard J Trabulsi, Costas D Lallas, Jianqing Lin, and William Kevin Kelly, Thomas Jefferson University Hospital, Philadelphia, PA Timothy A Brennan and Norma Palma, Foundation Medicine, Cambridge, MA and Stephen A Boorjian, Mayo Clinic, Rochester, MN
    J Clin Oncol 32:1895-901. 2014
  7. ncbi request reprint Circulating tumor cells: evolving evidence and future challenges
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncologist 14:1070-82. 2009

Detail Information

Publications7

  1. pmc A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    J Gastrointest Cancer 43:562-9. 2012
    ..This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients...
  2. pmc Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
    E Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Br J Cancer 106:748-55. 2012
    ..We correlated increased AURKA-CN in mCRC tumours with KRAS mutation status, overall and progression-free survival (OS, PFS)...
  3. pmc Challenges in the management of older patients with colon cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    J Natl Compr Canc Netw 10:213-24; quiz 225. 2012
    ..This review provides an overview of the available data regarding the management of older adults with colon cancer in the adjuvant and metastatic settings...
  4. pmc Challenges in the management of stage II colon cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Semin Oncol 38:511-20. 2011
    ..Additional research is necessary to clearly define the most appropriate way to use this marker and others in routine clinical practice...
  5. doi request reprint Optimizing chemotherapy regimens for patients with early-stage breast cancer
    Efrat Dotan
    Fox Chase Cancer Center, Philadelphia, PA 19111 2412, USA
    Clin Breast Cancer 10:E8-15. 2010
    ..This review summarizes the available tools that can assist in this process and provides an overview of the chemotherapy regimens approved for the adjuvant treatment of patients with early-stage breast cancer...
  6. pmc Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity
    Elizabeth R Plimack
    Elizabeth R Plimack, Rosalia Viterbo, Eric A Ross, Richard E Greenberg, David Y T Chen, Yu Ning Wong, Alexander Kutikov, Efrat Dotan, Essel Dulaimi, Reza Mehrazin, Robert G Uzzo, and Gary R Hudes, Fox Chase Cancer Center, Temple Health Jean H Hoffman Censits, Edouard J Trabulsi, Costas D Lallas, Jianqing Lin, and William Kevin Kelly, Thomas Jefferson University Hospital, Philadelphia, PA Timothy A Brennan and Norma Palma, Foundation Medicine, Cambridge, MA and Stephen A Boorjian, Mayo Clinic, Rochester, MN
    J Clin Oncol 32:1895-901. 2014
    ....
  7. ncbi request reprint Circulating tumor cells: evolving evidence and future challenges
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncologist 14:1070-82. 2009
    ..This review covers the different techniques available for isolation of CTCs, the clinical utility of CTCs in breast, prostate, and colon cancer, and future directions in this field...